Elevance earnings prompted a higher full-year outlook on October 21, 2026, as the health insurer reported third-quarter adjusted diluted earnings per share of $6.99 on operating revenue of $50.4 billion. The company raised its 2026 adjusted EPS guidance to at least $29.00 from $27.00, although quarterly results included a net non-operating benefit of $1.85 per share.
Key Takeaways
- Elevance raised its 2026 adjusted EPS floor by $2.00 and operating cash flow guidance to at least $6.5 billion.
- Carelon operating profit increased 17%, while Health Benefits profit declined and medical membership fell.
- Management’s 2027 growth expectation uses a $26.75 earnings baseline, not the headline $29.00 guidance floor.
Table of Contents
- Elevance earnings include a significant non-operating benefit
- Carelon growth offsets pressure in health insurance
- Higher guidance has a separate baseline for 2027
- Cash generation accompanies shareholder distributions
- Conclusion
Elevance earnings include a significant non-operating benefit
Elevance’s third-quarter results announcement showed operating revenue rising 0.7% from a year earlier. GAAP diluted EPS reached $6.27, compared with $5.32 in the third quarter of 2025.
The company attributed revenue growth to higher premium yields, increased CarelonRx product revenue and growth in service fees. Lower enrollment in Medicare Advantage, Medicaid and employer-group risk-based plans partly offset those gains.
The $1.85-per-share net non-operating benefit is important when assessing the quarter: the earnings result did not come entirely from operating performance. Consolidated operating gain was approximately $1.3 billion, down 2.0% year over year in the detailed financial statements.
| Item | Details |
|---|---|
| Parent-company cash and investments | Approximately $2.4 billion at September 30, 2026 |
| Third-quarter share repurchases | 0.8 million shares for $330 million |
| Remaining repurchase authorization | Approximately $5.0 billion at September 30, 2026 |
| Adjusted operating expense ratio | 11.3%, up 90 basis points year over year |
Carelon growth offsets pressure in health insurance
Carelon, which includes pharmacy and healthcare services, generated operating revenue of $19.3 billion, up 5% year over year. Operating gain increased 17% to approximately $0.9 billion, supported by risk-based services and improved specialty-pharmacy profitability.
Health Benefits operating revenue rose 3% to $43.4 billion, but operating gain declined to approximately $0.4 billion. Elevance attributed the decline to targeted investments, partly offset by an improvement in its benefit expense ratio.
That ratio, which measures benefit expenses against premiums, improved by 70 basis points to 90.6%, reflecting better performance in Medicare Advantage and individual Affordable Care Act plans. Medical membership nevertheless fell by 487,000 over the year to approximately 44.9 million at September 30, 2026.
Higher guidance has a separate baseline for 2027
Alongside its higher adjusted earnings forecast, Elevance raised full-year GAAP diluted EPS guidance to at least $22.00 and operating cash flow guidance to at least $6.5 billion. These are management forecasts, rather than completed results.
Chief Executive Officer Gail K. Boudreaux said the company remained confident in delivering at least 12% adjusted diluted EPS growth in 2027 from a 2026 baseline of at least $26.75.
That baseline excludes non-recurring net investment income and other non-operating items, as well as targeted one-time investments. The distinction means management’s 2027 growth expectation should not be applied directly to the $29.00 headline adjusted EPS guidance.
Cash generation accompanies shareholder distributions
Third-quarter operating cash flow increased by approximately $0.1 billion year over year to $1.3 billion, primarily reflecting favorable working-capital movements.
Elevance paid $373 million in dividends during the quarter. On October 20, the board’s Audit Committee also declared a fourth-quarter dividend of $1.72 per share, payable December 18, 2026, to shareholders of record at the close of business on December 4.
Conclusion
Elevance’s higher outlook reflects stronger performance in parts of its business, but non-operating income and a separate 2027 earnings baseline qualify the headline figures. The next confirmed shareholder milestone is the December 4 dividend record date, ahead of payment on December 18.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
